Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 208861, held by Actavis Elizabeth. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 208861 (Methylphenidate Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Dec 13, 2018, with 3 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. Limitations of Use The use of methylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2018 | Original application | Approved |
| Methylphenidate Hydrochloride10MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride15MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride30MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride40MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride50MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride60MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Aug 16, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 13, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters